- Home
- HIVE vs CRVS Comparison
HIVE vs CRVS Comparison
Compare HIVE & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HIVE | CRVS |
|---|---|---|
| Founded | 1987 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 580.6M | 546.7M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | HIVE | CRVS |
|---|---|---|
| Price | $2.38 | $20.41 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | $7.64 | ★ $28.00 |
| AVG Volume (30 Days) | ★ 13.7M | 7.8M |
| Earning Date | 02-13-2026 | 03-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $193,254,000.00 | N/A |
| Revenue This Year | $185.64 | N/A |
| Revenue Next Year | $44.55 | N/A |
| P/E Ratio | $11.82 | ★ N/A |
| Revenue Growth | ★ 57.09 | N/A |
| 52 Week Low | $1.26 | $2.54 |
| 52 Week High | $7.84 | $26.95 |
Technical Indicators
Market Signals| Indicator | HIVE | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 38.72 | 63.78 |
| Support Level | $2.00 | $18.92 |
| Resistance Level | $3.15 | $21.97 |
| Average True Range (ATR) | 0.23 | 2.08 |
| MACD | -0.08 | -0.32 |
| Stochastic Oscillator | 28.62 | 17.87 |
Price Performance
Historical ComparisonAbout HIVE HIVE Digital Technologies Ltd.
HIVE Digital Technologies Ltd is in the business of providing infrastructure solutions in the blockchain industry. It focuses on the mining and sale of digital currencies. Its geographical segments include Canada, Sweden, Iceland, Switzerland, and Bermuda, out of which the majority of the revenue comes from Bermuda.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).